Phase 1 Schizophrenia Trial, Recruiting NCT07061288 Sponsor: Bristol-Myers Squibb Condition: Schizophrenia
Back to Schizophrenia

Phase 1 Schizophrenia Trial, Recruiting

NCT07061288
Recruiting Phase 1

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have been formally diagnosed with schizophrenia, confirmed through a psychiatric assessment using recognised diagnostic tools and guidelines.
  • People whose schizophrenia symptoms are rated as moderate or below on two standard measurement scales, at both an initial screening appointment and a baseline appointment before the trial begins.
  • People whose body weight falls within a moderate range relative to their height (a body mass index between 18 and 40).
  • People who are willing and able, in the view of the trial doctor, to stop taking all antipsychotic medications before the trial begins and to follow all trial requirements throughout.

Who may not be able to join:

  • People who have been newly diagnosed with schizophrenia or are experiencing their first treated episode of the condition.
  • People who have been diagnosed with another mental health condition — such as major depression or bipolar disorder — within the past 12 months.
  • People who have had an alcohol or drug use disorder within the past 12 months, or who have another significant health condition that could affect their safety or the reliability of the trial results.
  • People who are considered to be at risk of suicidal behaviour.
  • People who are currently pregnant or breastfeeding.
  • Additional criteria set by the trial may also apply (confirm with trial site).

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 26 July 2026
Phase 1: approximately ~10% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Bristol-Myers Squibb, Bristol-Myers Squibb

Phone: 855-907-3286

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 1
Registry
ClinicalTrials.gov
Start date
3 September 2025
Est. completion
21 June 2027

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Number of participants with adverse events (AEs); Number of participants with adverse events of special interest (AESIs); Number of participants with serious adverse events (SAEs)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov